Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Resistance to β-lactam antibiotics is rapidly growing, substantially due to the spread of
serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs), which efficiently catalyse β …

Cefiderocol has been approved in the United States and Europe but not in China. We aim to
evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to …

Carbapenem-resistant Enterobacterales (CRE) remain a significant public health threat,
and, despite recent approvals, new antibiotics are needed. Severe infections caused by …

Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities.
Although cefiderocol has not been approved in China, resistance is emerging. A multicenter …

Background Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability
toward β-lactamases, including carbapenemases, achieved by combining structural …

Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat
(DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas …

Introduction Novel last resort beta-lactam antibiotics are now available for management of
infections due to New-Delhi Metallo-Beta-Lactamase (NDM) producing Enterobacterales …

Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and
mortality of GNB infection, seriously threaten human health globally. Developing new …

Antimicrobial resistance represents a serious threat for global health, causing an
unacceptable burden in terms of morbidity, mortality and healthcare costs. In particular, in …